Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05033288 · ClinicalTrials.gov registry record
Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone
A clinical trial of Chordoma and Chondrosarcoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 72
- Enrollment target
- 3
- Study locations
NCT05033288: Recruiting study of Chordoma and Chondrosarcoma, sponsored by Mayo Clinic.
NCT05033288 is a study of Chordoma and Chondrosarcoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 72 participants, below the 82-participant average among 15 other Chordoma trials with a reported enrollment target (12% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05033288, a study of Chordoma and Chondrosarcoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 72 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study compares carbon ion therapy, surgery, and proton therapy to determine if one has better disease control and fewer side effects. There are three types of radiation treatment used for pelvic bone sarcomas: surgery with or without photon/proton therapy, proton therapy alone, and carbon ion therapy alone. The purpose of this study is to compare quality of life among patients treated for pelvic bone sarcomas across the world, and to determine if carbon ion therapy improves quality of life compared to surgery and disease control compared with proton therapy.
Primary Outcome
Will be compared between patients who received carbon ion radiation therapy (CIRT) and surgery utilizing a one-sided test for a two sample t-test for independent means. The Patient Reported Outcomes Measurement Information System (PROMIS)-29 functional score will be calculated and median, mean, and 95% confidence interval will be computed for each arm, with one-sided two-sample t-tests conducted between the surgery +/- radiation therapy (RT) and CIRT arm.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Electronic Health Record Review
Study Locations (3)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Florida
- Mayo Clinic in Florida - Jacksonville
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2022-01-20 |
| Est. Completion | 2031-08-30 |
What NCT05033288 shows while recruiting
NCT05033288 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 82-participant average among 15 other Chordoma trials with a reported enrollment target (12% lower).
The record links to 5 conditions, with Chordoma appearing as the primary indexed condition, and to 2 interventions - of which Quality-of-Life Assessment is the first listed.
NCT05033288 reports a single indexed study location in Arizona, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05033288 about?
NCT05033288 is a clinical study titled "Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone". This study compares carbon ion therapy, surgery, and proton therapy to determine if one has better disease control and fewer side effects. There are three types of radiation treatment used for pelvic bone sarcomas: surgery with or without photon/proton therapy, proton therapy alone, and carbon ion t...
What is the current status of trial NCT05033288?
This trial is currently recruiting. The enrollment target is 72 participants. The study started on 2022-01-20. Estimated completion is 2031-08-30.
What conditions does trial NCT05033288 study?
This clinical trial studies the following conditions: Chordoma, Chondrosarcoma, Bone Sarcoma, Ewing Sarcoma of Bone, Pelvic Rhabdomyosarcoma.
What interventions are being tested in trial NCT05033288?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Electronic Health Record Review (OTHER).
Who is sponsoring clinical trial NCT05033288?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05033288 being conducted?
This trial has 3 study locations across Arizona, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chordoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05033288's enrollment target sits among peer trials
72 4th of 15 higher than 12 of 15 other Chordoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chordoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Children and Adults With Chordoma
RECRUITING
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
RECRUITING · Phase 1
-
Pembrolizumab and Pemetrexed for Progressive Chordoma
RECRUITING · Phase 2
-
Long-Term Longitudinal QoL in Patients Undergoing EEA
RECRUITING
-
A Study of ERAS-601 in People With Chordoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI